Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKURABONSAI
2021-001088-26Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 cohorts), sponsored by Roche. Primary endpoint: Clinical measures related to disease activity and progression over 96 weeks. Started Oct 2021; status: terminated.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2021-001088-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001088-26.